Treatment of Subacute Cutaneous Lupus Erythematosus in Pregnancy or Breastfeeding
Clinical scenario
Active SCLE (EB50 / L93.1) occurring during pregnancy or breastfeeding requires a carefully selected treatment strategy. The first-line approach for CLE in this setting is established, but cases where it proves insufficient call for a specific alternative protocol that accounts for the safety constraints of pregnancy and lactation.
Treatment approach — partial overview
When standard first-line therapy has not achieved adequate disease control, the protocol calls for a specific agent used at a low starting dose and adjusted according to clinical response. Full sequencing, dose titration guidance, and decision criteria are in the complete protocol below.
References
- In active disease during pregnancy or breastfeeding, we recommend HCQ as first line treatment for CLE at usual dosage.
- In active disease or during flares, we suggest dapsone for HCQ-refractory CLE patients as an alternative treatment in during pregnancy or breastfeeding.
- We recommend to start dapsone with a low dose treatment (50 mg/day) and to increase it to a maximum of 1.5 mg/kg according to clinical response and side-effects.